E-MAIL
hongjaan@mail.ndmctsgh.edu.tw
Experience
07/1999–05/2014 Airforce R.O.C.
06/2014–06/2015 Faculty, School of Pharmacy, National Defense Medical Center
07/2015–07/2019 Assistant professor, School of Pharmacy, National Defense Medical Center
10/2017-03/2018 Visiting scholar in UCSF (Lab of Leslie Z. Benet)
08/2019–present Associate professor, School of Pharmacy, National Defense Medical Center
08/2022–present Dean, School of Pharmacy, National Defense Medical Center
07/2015–06/2020 Scientific consultant of Sinew Pharma Inc.
01/2017–present Editorial board of the Chinese Pharmacopoeia
01/2019–12/2021 Deputy Convener of the Chinese Pharmacopoeia Compilation Advisory Council (General Pharmaceutics Group)
01/2022–present Convener of the Chinese Pharmacopoeia Compilation Advisory Council (General Pharmaceutics Group)
07/2015–06/2020 Scientific consultant of Sinew Pharma Inc.
Research Interest
Pharmacokinetics and pharmacodynamics,
Drug metabolism, Enzyme kinetics
Short Biography
Dr. Hong-Jaan Wang is currently an Associate professor in the School of Pharmacy at National Defense Medical Center, Republic of China (Taiwan). He received his B.S. and M.S. from the School of Pharmacy and obtained Ph.D. from the Graduate Institute of Life Sciences at National Defense Medical Center. His research interests are focused on pharmacokinetics and drug metabolism. He has developed an oral dosage form for a non-controlled opiate which was clinically used with only injectable form over the past years. The research activities include formulation development, identification of drug metabolites, diverse analytical methods in drug determination, and the finding of pharmacokinetic properties. In addition to a role of school faculty, Dr. Wang is a scientific consultant of Sinew Pharma Inc. in the aspects of new drug development and clinical study.
Publications
1. HJ Wang, LH Pao, CH Hsiong, TY Shih, MS Lee, OYP Hu*. Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship. AAPS J. 2014, 16(2): 258–268. (IF 4.39, 37/261, 2012 JCR)
2. HJ Wang, CH Hsiong, ST Ho, MJ Lin, TY Shih, PW Huang, OYP Hu*. Commonly used excipients modulate UDP-glucuronosyltransferase 2B7 activity to improve nalbuphine oral bioavailability in humans. Pharm Res. 2014, 31(7): 1676-1688. (IF 4.74, 26/261, 2012 JCR)
3. HJ Wang, CH Hsiong, LH Pao, WL Chang, LJ Zhang, MJ Lin, ST Ho, PW Huang, OYP Hu*. New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC–MS/MS spectrometry assays in a pilot human study. Metabolomics. 2014, 10(4): 709–718. (IF 4.43, 29/122, 2012 JCR)
4. YF Ueng*, CK Lu, SH Yang, HJ Wang, CC Huang. Potentiation of the anticoagulation effect of warfarin by the herbal remedy shu-jing-hwo-shiee-tang in rats: The dosing regimen and pharmacokinetic interaction. Drug Metab Pharmacokinet. 2017, 32(1): 85–91. (IF 1.76, 168/255, 2015 JCR)
5. HJ Wang, CK Lu, WS Kuo, WC Chen, YF Ueng*. Shenmai-Yin decreased the clearance of nifedipine in rats: The involvement of time-dependent inhibition of nifedipine oxidation. J Food Drug Anal. 2019, 27(1): 284–294. (IF 2.85, 33/133, 2017 JCR)
6. WC Chen, PW Huang, WL Yang, YL Chen, YN Shih, HJ Wang*. Fundamentals of pharmacokinetics to assess the correlation between plasma drug concentrations and different blood sampling methods. Pharm Res. 2019, 36(2): 32. (IF 3.34, 74/261, 2017 JCR)
7. KT Lin, SW Lai, SD Hsu, CY Fan, HJ Wang, PK Chang, WH Liu, YL Chen, IC Yen, SY Lee*. Shoulder pain and risk of developing hypertension and cardiovascular disease: A nationwide population-based cohort study in Taiwan. J Med Sci. 2019, 39(3):127–134.
8. RJ Liang†, YH Lai†, YT Kao, TH Yang, YL Chen, HJ Wang*. A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation. Eur J Med Chem. 2019, 178:544–551. (IF 4.82, 4/59, 2017 JCR)
9. YF Ueng†, HJ Wang†, SC Wu, YY Ng*. A practical thrice weekly ertapenem to avoid neurotoxicity in hemodialysis patients. Antimicrob Agents Chemother. 2019, 63(12): e01427–19. (IF 4.72, 27/267, 2018 JCR)
10. HJ Wang and LZ Benet*. Protein binding and hepatic clearance: Re-examining the discrimination between models of hepatic clearance with diazepam in the isolated perfused rat liver preparation. Drug Metab Dispos. 2019, 47(12):1397–1402. (IF 3.35, 82/267, 2018 JCR)
11. RJ Liang†, YN Shih†, YL Chen, WY Liu, WL Yang, SY Lee, HJ Wang*. A dual system platform for drug metabolism: Nalbuphine as a model compound. Eur J Pharm Sci. 2020, 141:105093. (IF 3.53, 71/267, 2018 JCR)
12. JK Sodhi, HJ Wang, LZ Benet*. Are there any experimental perfusion data that preferentially support the dispersion and parallel tube models over the well-stirred model of organ elimination? Drug Metab Dispos. 2020, 48(7):537–543. (IF 3.35, 82/267, 2018 JCR)
13. TY Chiang, HJ Wang, YC Wang, ECH Tan, IJ Lee, CH Yun, YF Ueng*. Effects of Shenmai San on hepatic and intestinal cytochrome P450s, glutathione S-transferase, uridine diphosphate-glucuronosyltransferase and NADPH-quinone oxidoreductase in rats. J Ethnopharmacol. 2021, 271:113914. (IF 3.69, 3/28, 2019 JCR)
14. SH Hsu, AC Cheng, TY Chang, LH Pao, CH Hsiong, HJ Wang*. Precisely adjusting the hepatic clearance of highly extracted drugs using the modified well-stirred model. Biomed Pharmacother. 2021, 141:111855. (IF 6.53, 25/276, 2020 JCR)
15. HJ Wang†, ECH Tan†, TY Chiang, WC Chen, CC Shen, YF Ueng*. The risks and benefits of herb-drug co-treatment on nifedipine and Shengmai-San: Bench and population-based studies. J Food Drug Anal. 2022, 30(1):111–127. (IF 6.08, 12/143, 2020 JCR)
16. TY Chang, HJ Wang, SH Hsu, ML Chang, LT Kao*, LH Pao*. Evidence of the need for modified well-stirred model in in vitro to in vivo extrapolation. Eur J Pharm Sci. 2022, 177:106268. (IF 5.11, 74/279, 2021 JCR)
17. RJ Liang, SH Hsu, TY Chang, TY Chiang, HJ Wang*, YF Ueng*. Metabolism-involved drug interactions with traditional Chinese medicine in cardiovascular disease. J Food Drug Anal. 2022, xx(x):xxx–xxx. (IF 6.16, 45/279, 2021 JCR) Accepted.
18. HJ Wang, AC Chen, CK Lu, LT Kao, WC Chen, IJ Lee, YF Ueng*. Effects of the herbal formula Xin-yi-san on the oxidation and pharmacokinetics of theophylline in rats. Draft.
19. HY Hung, YL Chen, HJ Wang*. A potent active metabolite nalbuphine-6-glucuronide: new perspective of its antinociceptive effect. Draft.
Patent
1. Oliver Yoa-Pu Hu, Hong-Jaan Wang, Cheng-Huei Hsiong, Li-Heng Pao. Cytochrome P450 2C9 inhibitors. 2008, ROC I 299002 (term 2024/4/4)
2. Oliver Yoa-Pu Hu, Hong-Jaan Wang. New administration route, new oral dosage form and new dose of nalbuphine. 2013, ROC I 397413 (term 2030/10/28)
Research Proposal
1. The metabolism of kappa receptor agonist and genetic polymorphism studies of its responsible enzyme. (2014/08-2016/07, MOST 103-2320-B-016-007-MY3)
2. Using different mechanical pain tests in rats to investigate the correlation between pharmacokinetic and pharmacodynamic effects of multimodal analgesics. (2016/01-2016/12, 105A23)
3. Enzyme kinetic study of opioid analgesic－nalbuphine. (2017/01-2017/12, MAB-106-078)
4. The study of opioid analgesic－nalbuphine: High yield chemical synthesis of nalbuphine-3-glucuronide and the active metabolite nalbuphine-6-glucuronide. (2018/01-2018/12, 805-C107-10)
5. On the basis of pharmacokinetic to assess the correlation between plasma drug concentrations and different blood sampling methods. (2018/04-2019/03, MOST 106-2320-B-016-001)
6. The divergence of determined blood concentrations of biopharmaceutical drug disposition system class I and IV clinical drugs in small animals. (2019/01-2019/12, 805-C108-13)
7. The suitability and accuracy using isolated rat liver perfusion model to predict drug hepatic clearance. (2020/01-2020/12, HAFGH-E-109019)
8. Herbal-drug interactions in chronic cardiovascular disease: Schisandra Fructus influence the pharmacokinetic of nifedipine. (2020/01-2020/12, HAFGH-E-109013)
9. A novel opioid analgesic nalbuphine-6-glucuronide: Mechanism, pharmacokinetic and drug development study. (2020/08-2021/07, MOST 109-2320-B-016-011)
10. A new sustained release formulation of nalbuphine combined with acetaminophen to prolong pain-relief efficacy and reduce nalbuphine-induced dysphoria. (2021/01-2021/12, HAFGH-E-110020)
11. Optimization of liver microsomal incubation to accurately predict drug metabolism from in-vitro to in-vivo extrapolation. (2021/01-2021/12, HAFGH-E-110013)
12. What went wrong with the well-stirred model used to predict drug hepatic clearance over the past half-century? (2021/08-2022/07, MOST 110-2320-B-016-007)
13. Application of 3D printing in microfluidic encapsulating technology to improve the oral bioavailability of penicillin (2022/01-2022/12, 801GB111252)
14. Physicochemical properties of the drug determine the accuracy of the liver metabolic models in predicting plasma drug concentration. (2022/01-2022/12, HAFGH_E_111015)
15. The suitability and accuracy using isolated rat liver perfusion model to predict drug hepatic clearance. (2022/01-2022/12, HAFGH_D_111012)
16. A novel hepatic clearance model being used as the basis for evaluating liver metabolism of drugs: theoretical research and applicability analysis (1/2) (2022/01-2022/12, CMRPF1M0041)
Conference Papers
1. HJ Wang, WL Chang, MJ Lin, PW Huang, OYP Hu. New Finding of Nalbuphine Metabolites in Men: NMR Spectroscopy and UPLC–MS/MS Spectrometry Assays in a Pilot Human Study. 41th Military Medical Academic Conference, Taipei, Taiwan. Nov 2014.
2. H-J. Wang, C-H. Hsiong, S-T. Ho, M-J. Lin, T-Y. Shih, P-W. Huang, O. Y-P. Hu, Commonly Used Excipients Modulate UGT2B7 Activity to Improve Nalbuphine Oral Bioavailability in Humans. 29th American Association of Pharmaceutical Scientists (AAPS), Orlando, USA. Oct 25-29, 2015.
3. H-J. Wang, L-H. Pao, C-H. Hsiong, T-Y. Shih, M-S. Lee, O. Y-P. Hu, Dietary Flavonoids Modulate CYP2C to Improve Drug Oral Bioavailability and Their Qualitative/Quantitative Structure–Activity Relationship. 29th American Association of Pharmaceutical Scientists (AAPS), Orlando, USA. Oct 25-29, 2015.
4. Yan-Lun Chen, Tsan-Seng Hsiao, Hsin-Cheng Lin, Hong-Jaan Wang, The Synergistic Effects of Pain Relief Exerted from the Combination of Morphine, Diclofenac and Acetaminophen. 43th Military Medical Academic Conference, Taipei, Taiwan. Nov 2016.
5. H-J. Wang, Y-L Chen, O. Y-P. Hu, Potent Analgesic Effect of Nalbuphine-6-Glucuronide: Chemical Synthesis, Pharmacokinetic Assessment, and Antinociceptive Evaluation. 31th American Association of Pharmaceutical Scientists (AAPS), San Diego, USA. Nov 11-15, 2017.
6. H-J Wang (Inviting Speech), What's wrong with the well-stirred model in predicting drug hepatic clearance? 2nd Joint Academic Annual Meeting of Pharmaceutical Society of Taiwan, Taipei, ROC. Nov. 08, 2020.